Medically appropriate following treatment with ANDEXXA. To reduce thromboembolic risk, resume anticoagulant therapy as soon as Monitor patients treated with ANDEXXA for signs and symptoms of arterial and venous thromboembolic events, Of these 223, 18 subjects (8%) had a thrombotic Of the 352 subjects who received ANDEXXA, 223 received at least one anticoagulation dose A total of 63 (18%) experienced 88 thromboembolic or Subjects who experienced a thrombotic event, the median time to first event was 7Įxperienced the event within the first three days. The thromboembolic and ischemic risks were assessed in 352 bleeding subjects who received ANDEXXA. Select Important Safety Information WARNINGS AND PRECAUTIONS
0 kommentar(er)
